Clinical Trial Update: Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a fixed-ratio combination of insulin glargine and lixisenatide in adults with type 2 diabetes inadequately controlled by oral agents; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• insulin glargine/lixisenatide fixed-ratio combination (insulin glargine, lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED